TOVX · All filings · Read this filing

What changed 10-Q

Item 5. Other Information

2023-08-08 compared with 2023-05-11 · 3 added, 2 removed, 43 unchanged (10% of the section changed)

7 unchanged sentences

(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

August 8, 2023

EXHIBIT INDEX

18 unchanged sentences

Separation Agreement dated as of May 8, 2023 between Theriva Biologics, Inc.

and Frank Tufaro

and Frank Tufaro (Incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, File No.

Consulting Agreement dated as of May 8, 2023 between Theriva Biologics, Inc.

and Frank Tufaro

and Frank Tufaro (Incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, File No.

Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a)*

13 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.